IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorInnovent Biologics (Suzhou) Co. Ltd.
About this trial
This is a Phase 2 study to evaluate the safety, and efficacy of IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer.
Eligibility criteria
Qualifiers
Males and Females, age ≥18 years and ≤75 years;
Stage II, IIIA or IIIB (N2) NSCLC (per AJCC8);
No administration of any anti-NSCLC therapy in the pre-operative period;
Be able to undergo the radical resection; Pulmonary function capacity capable of tolerating the proposed lung resection according to the surgeon.
Disqualifiers
Histologically confirmed the presence of small cell lung cancer, neuroendocrine carcinoma, sarcoma, salivary gland tumor, and mesenchymal tumor components, or mixed NSCLC with predominant squamous cell carcinoma features;
Tumor invasion of surrounding important structures, which is symptomatic or medical intervention indicated;
Pancoast tumor;
Malignant tumor nodule in the contralateral lung lobe;
Trial design
Treatments tested in this trial
- IBI363
Treatment groups
10 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov